European Commission Expands Merck’s ERVEBO®Indication to Include Children 1 Year of Age and Older

European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older

Merck known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved an expanded indication for ERVEBO for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire ebolavirus. The EC’s decision follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) received on July 20, 2023. The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older. The use of ERVEBO should be in accordance with official recommendations.

“Ebola virus disease is severe and potentially life-threatening for both children and adults. The European Commission’s expanded approval of ERVEBO for children 1 year of age and older is an important milestone for the prevention of disease caused by Zaire ebolavirus,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. “When outbreaks of Ebola virus disease occur, they can quickly become a public health crisis. We are proud to play a role, alongside the global public health community, in helping to prepare for potential outbreaks of Zaire ebolavirus.”

In January 2021, Merck confirmed an agreement with UNICEF to establish the world’s first global Ebola vaccine stockpile with ERVEBO to support future Zaire ebolavirus outbreak preparedness and response efforts. To date, over 500,000 doses of the licensed vaccine have been delivered to the stockpile, which is administered by the International Coordinating Group on Vaccine Provision.

Source link:https://www.merck.com/media/news/

Newsletter Updates

Enter your email address below and subscribe to our newsletter